newsfilter
← Latest News
Business Wire·

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose ---- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --Xencor, Inc.